17:48 , May 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Dual activation of JNK1 and JNK2 for STK11-deficient lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest dual activation of JNK1 and JNK2 could help treat STK11-deficient squamous cell carcinoma (SCC) of the lung. In patients, low tumor...
20:28 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Auris reports additional Phase III data of brimapitide for hearing loss

Auris Medical Holding AG (NASDAQ:EARS) reported additional data from the Phase III HEALOS trial evaluating single intratympanic doses of 0.4 and 0.8 mg/mL brimapitide (AM-111, D-JNKI-1, XG-102) gel in 256 patients with severe to profound...
22:03 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Auris misses in Phase III hearing loss trial

Auris Medical Holding AG (NASDAQ:EARS) stock fell 49% Nov. 28 after the company said brimapitide (AM-111) missed the primary endpoint in the Phase III HEALOS trial. Neither tested dose of intratympanic brimapitide gel significantly improved...
22:31 , Nov 28, 2017 |  BC Extra  |  Clinical News

Auris' lead candidate misses in Phase III hearing loss trial

Auris Medical Holding AG (NASDAQ:EARS) fell $0.40 (49%) to $0.42 Tuesday after it said brimapitide (AM-111) missed the primary endpoint in the Phase III HEALOS trial. Neither tested dose of intratympanic brimapitide gel significantly improved...
21:50 , Oct 5, 2017 |  BC Innovations  |  Translation in Brief

Chronic neuroprotection

Two studies by Genentech have shown DLK inhibition is neuroprotective in two chronic neurodegenerative diseases and suggest the target may play a broad role in driving neurodegeneration, regardless of the underlying cause. MAP kinase kinase...
23:34 , Jun 15, 2017 |  BC Innovations  |  Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc. , Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
02:11 , Feb 23, 2017 |  BC Week In Review  |  Clinical News

Brimapitide: Ph II data

A double-blind, placebo-controlled, French Phase II trial in 145 patients with post-operative intraocular inflammation showed that a single 900 μg subconjunctival injection of brimapitide given at the end of ocular surgery met the primary endpoint...
17:56 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Candida Mouse studies suggest inhibiting JNK1 could help treat Candida albicans infection. In a mouse model of C. albicans infection, knockout of JNK1 or two JNK1 inhibitor tool compounds decreased fungal burden and inflammation...